Compare Deckers Outdoor Corp (DECK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Viatris Inc — how do they compare? Deckers Outdoor Corp trades at $82.62 (market cap $10.95B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.74% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Viatris Inc for 57 Days on average.
| DECK | VTRS | |
|---|---|---|
Market Cap | $10.95B | $20.12B |
Volume | 3,090,240 | 7,543,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $18.27 |
52-Week Low | $77.51 | $9.74 |
Typical Hold Time | 71 Days | 57 Days |
Enterprise Value | $9.82B | $32.24B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $80.38, down 1.57% today, with strong fundamentals including 19.37% net margin and consistent earnings beats. The stock shows neutral technical signals with support at $78-79 and resistance at $81-82. Revenue growth has accelerated from $3.2B in 2022 to $5.0B in 2025, while profitability metrics remain robust with 42.56% ROE.
DECK presents a compelling value opportunity with attractive valuation multiples (P/E 11.43, EV/EBITDA 7.06) and 46% upside to consensus price target of $117.13. Risks include potential margin pressure from competitive footwear market and projected negative cash flow in 2026. Analyst sentiment leans bullish with 45% buy ratings versus 11% sell recommendations.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
